TLPH · Talphera, Inc. · Executive Compensation
$0.79
+0.05 (+6.25%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
Market Cap
$40.80M
Shares
51.96M
Volume · Nov 20
357.32K
Avg daily vol (3M)
144.24K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | CEO | $1,117,277 |
| Raffi Asadorian | Chief Financial Officer | $727,309 |
| Shakil Aslam | Chief Medical Officer | $654,840 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | CEO | $1,038,992 |
| Raffi Asadorian | Chief Financial Officer | $709,857 |
| Badri Dasu | Chief Engineering Officer | $575,959 |
| Shakil Aslam | Chief Medical Officer | $529,242 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | CEO | $1,211,994 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $814,270 |
| Raffi Asadorian | Chief Financial Officer | $742,609 |
| Badri Dasu | Chief Engineering Officer | $602,166 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | CEO | $1,297,016 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $822,400 |
| Raffi Asadorian | Chief Financial Officer | $755,144 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | CEO | $2,447,954 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $1,083,507 |
| Raffi Asadorian | Chief Financial Officer | $1,024,610 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | CEO | $1,765,522 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $962,122 |
| Raffi Asadorian | Chief Financial Officer | $890,716 |
| Badri Dasu | Chief Engineering Officer | $686,353 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | CEO | $2,125,052 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $1,083,333 |
| Raffi Asadorian | Chief Financial Officer | $1,013,492 |
| Badri Dasu | Chief Engineering Officer | $776,258 |
| Lawrence G. Hamel | Former Chief Development Officer | $776,018 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | CEO | $1,738,845 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $1,063,956 |
| Raffi Asadorian | Chief Financial Officer | $907,235 |
| Badri Dasu | Chief Engineering Officer | $734,208 |
| Lawrence G. Hamel | Former Chief Development Officer | $688,617 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | CEO | $2,353,923 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $874,093 |
| Raffi Asadorian | Chief Financial Officer | $606,287 |
| Badri Dasu | Chief Engineering Officer | $595,179 |
| Lawrence G. Hamel | Former Chief Development Officer | $595,179 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mark Wan | Class III director | Appointed | 2026-06-23 |
| Joseph Todisco | Class III director | Appointed | 2026-06-23 |
| Marina Bozilenko | Class III director | Appointed | 2026-06-23 |
| Abhinav Jain | Class II director | Appointed | 2025-10-24 |
| Stephen J. Hoffman | Class II director | Appointed | 2025-10-24 |
| Vincent J. Angotti | Class II director | Appointed | 2025-10-24 |
| Joseph Todisco | Class III member of the board of directors and member of the compensation committee | Appointed | 2025-10-16 |
| Shakil Aslam | Chief Development Officer | Appointed | 2024-08-14 |
| Shakil Aslam | Chief Medical Officer | Appointed | 2024-08-14 |
|
Pamela P. Palmer, MD, PhD
“Dr. Palmer's decision to resign is not the result of any dispute or disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
|
Chief Medical Officer | Resigned | 2024-08-14 |
| Jill Broadfoot | Class I director | Appointed | 2024-06-24 |
| Adrian Adams | Class I director | Appointed | 2024-06-24 |
|
Howard B. Rosen
“Dr. Afable and Mr. Rosen's resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
member of the board of directors | Resigned | 2024-03-01 |
|
Pamela P. Palmer, M.D., Ph.D.
“Dr. Palmer's resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
member of the Company's board of directors | Resigned | 2024-03-01 |
|
Richard Afable, M.D.
“Dr. Afable and Mr. Rosen's resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
member of the board of directors | Resigned | 2024-03-01 |
| Abhinav Jain | Class II Director | Appointed | 2024-01-22 |
| Mark Wan | Class III director | Appointed | 2023-10-10 |
| Howard B. Rosen | Class III director | Appointed | 2023-10-10 |
| Marina Bozilenko | Class III director | Appointed | 2023-10-10 |
|
Mark G. Edwards
“The resignation is not a result of any disagreement between Mr. Edwards and AcelRx Pharmaceuticals, Inc.”
|
member of the board of directors | Resigned | 2022-03-01 |
| Jill M. Broadfoot | Class I director of the Board | Appointed | 2021-11-23 |
| Marina Bozilenko | Class III director of the Board | Appointed | 2021-03-31 |
Leadership
- Vincent J. Angotti CEO, Board Member
- Raffi Asadorian CFO
- Abhinav Jain Board Member
- Adrian Adams Board Member
- Howard B. Rosen Board Member
- Jill Broadfoot Board Member
- Jill M. Broadfoot Board Member
- Joseph Todisco Board Member
- Marina Bozilenko Board Member
- Mark Wan Board Member
- Stephen J. Hoffman Board Member
Key facts
CIK
1427925
CUSIP
00444T209
13F (30d)
57 filings
49 filers
Visit website
Investor relations